February 15, 2005 -- Aphton Corp. reported that Insegia, in a Phase III trial against pancreatic cancer, failed to show a survival benefit, the primary endpoint of the test. Insegia was administered as an adjuvant to traditional chemotherapy. Following the announcement, the company’s stock was cut nearly in half, dropping 46% in trading on Tuesday. Nevertheless, the company remained upbeat about the trial’s results. Read why...
